Following the Series A investment, Drs. Mansoor Raza Mirza, Ronald DePinho, and Michael Kauffman will comprise the Board of Directors. Dr. Mirza, M.D. is Chief Oncologist at the Department of Oncology, Rigshospitalet - the Copenhagen University Hospital, Denmark. Dr. DePinho is the Director of the Belfer Institute for Applied Cancer Science and Professor of Medicine and Genetics at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Giulio Draetta, M.D., Ph.D., a leader in cancer drug development, is Deputy Director of the Belfer Institute and Chief Research Business Officer at the Dana-Farber Cancer Institute. Dr. Draetta will chair the Scientific Advisory Board.
About Karyopharm Therapeutics Inc.
Karyopharm is a privately held oncology company headquartered in Newton, Massachusetts. The Company was founded in 2009 by Drs. Sharon Shacham, Michael Kauffman, Ronald DePinho, and Giulio Draetta. Karyopharm's founding team and scientific advisory board have demonstrated entrepreneurial success in developing project ideas to productive clinical outcomes. The company is focused on the development of modulators of nuclear transport as novel therapies for cancer, inflammatory and other diseases. With the recent determination of the 3-dimensional structure of the nuclear pore complex, the mechanisms of nuclear transport have become more apparent. Many key tumor suppressor and growth regulatory proteins are exported from the nucleus by the major export prot
|SOURCE Karyopharm Therapeutics Inc.|
Copyright©2010 PR Newswire.
All rights reserved